GO
Loading...

Novartis AG

More

  • NEW YORK, April 24- Teva Pharmaceutical Industries' bid for Mylan NV would create a company controlling nearly 25 percent of the U.S. generics market, including drugs in short supply, according to industry experts and a Reuters review of regulatory filings. It is also pursuing a hostile takeover of drugmaker Perrigo Co Plc. Teva has already looked at the...

  • DETROIT, April 24- General Motors Co Chief Executive Officer Mary Barra, who last year became the first woman to lead a major U.S. automaker, received $16.2 million in 2014 compensation, up 78 percent from her predecessor's total the previous year. She received $4.55 million in salary and other liquid compensation for 2014, GM said in a proxy filed on Friday with...

  • DETROIT— General Motors CEO Mary Barra's compensation more than tripled in 2014 to $15.8 million in her tumultuous first year in the automaker's top job. Almost immediately, she was hit with a series of embarrassing safety recalls that led to congressional hearings, a Justice Department investigation and a $35 million fine from U.S. safety regulators.

  • April 23- Eli Lilly and Co soundly beat quarterly profit estimates on lower-than-expected spending on research and marketing but stuck to its full-year earnings forecast while revenue fell but matched expectations. Lilly earned $530 million, or 50 cents per share, in the quarter, compared with $728 million, or 68 cents per share, a year earlier..

  • The Indianapolis- based drugmaker posted a net profit of $529.5 million, or 50 cents per share, for the first quarter ended March 31, compared with a profit of $727.9 million, or 68 cents per share, a year earlier. In January, the company forecast full-year adjusted earnings of $3.10- $3.20 per share, and sales of $19.50- $20 billion. Lilly on Thursday cut its full-year...

  • Swiss exports defy franc surge on U.S., Asia strength Thursday, 23 Apr 2015 | 4:37 AM ET

    ZURICH, April 23- Swiss exports pushed higher in March despite the franc currency's sharp rise against the euro, as surging shipments to the United States, Middle East and Asia more than compensated for a drop-off in sales to the single currency bloc. Sales to the euro zone were down 3.7 percent on a nominal basis, while exports to the United States and Middle East...

  • FRANKFURT, Germany— Swiss-based pharmaceutical company Novartis reported a large jump in first-quarter net profit Thursday as it recorded one-time gains from deals with other drug companies. Novartis sold its animal health business to Lilly. It also bought cancer drugs from GSK and sold its non-flu vaccines business, while Novartis and GSK combined their...

  • Stocks turn lower after weak global economic surveys Thursday, 23 Apr 2015 | 12:16 AM ET

    TOKYO— Shares turned lower in European trading on Thursday, sapped by gloomy manufacturing data from the eurozone, China and Japan. HSBC bank said a preliminary version of its index based on a survey of factory purchasing managers in China fell to its lowest point in a year in April. EARNINGS: In corporate earnings, networks giant Ericsson was its shares slide 8...

  • Earnings next test for stocks after market wipeout Monday, 20 Apr 2015 | 5:52 AM ET
    Traders work on the floor of the New York Stock Exchange.

    Stocks could chop around and rack up more losses in the week ahead, with the next wave of corporate earnings reports.

  • Earnings next test for stocks after market wipeout Friday, 17 Apr 2015 | 4:29 PM ET
    Traders work on the floor of the New York Stock Exchange.

    Stocks could chop around and rack up more losses in the week ahead, with the next wave of corporate earnings reports.

  • Biotech investors brace for updates on key drugs Friday, 17 Apr 2015 | 1:44 PM ET
    Lab technician handling test tubes

    Biotech investors are going to be busy with new data on Alzheimer's drugs, cancer and genetic disorders on the way. Here's what analysts are watching.

  • The generic, called Glatopa, is made by Sandoz, a unit of Swiss drug company Novartis AG, and U.S.-based Momenta Pharmaceuticals. The Food and Drug Administration approved the drug Thursday. But Teva Pharmaceutical Industries, which makes Copaxone, has said it expects generic versions of the drug to go on sale in the U.S. in September.

  • The copied 20 mg version of the blockbuster drug, submitted by Sandoz, a unit of Swiss drugmaker Novartis AG, can be labeled "substitutable" for Copaxone, meaning that prescriptions for the brand-name drug can be automatically switched to the generic. The generic drug, called Glatopa, was developed collaboratively by Novartis and Momenta Pharmaceuticals Inc...

  • April 16- Momenta Pharmaceuticals Inc said the U.S. Food and Drug Administration approved the first generic version of Teva Pharmaceuticals Industries Ltd's top-selling multiple sclerosis drug, Copaxone. The agency cleared the application for the 20 mg version of the blockbuster drug, submitted by Momenta's partner Sandoz, a unit of Swiss drugmaker...

  • FDA approves new type of heart failure drug from Amgen Wednesday, 15 Apr 2015 | 4:53 PM ET

    TRENTON, N.J.— Patients with chronic heart failure, a disabling, deadly disease that worsens as the heart gradually pumps less efficiently, are getting a much-needed new option with U.S. approval Wednesday of a novel drug from Amgen Inc.. Meanwhile, the Food and Drug Administration is reviewing another heart failure pill, from Novartis AG, and could approve it this...

  • UPDATE 1-Aduro IPO pricing values drugmaker at $1 bln Tuesday, 14 Apr 2015 | 6:23 PM ET

    Aduro, which counts Johnson& Johnson and Swiss drugmaker Novartis AG among its investors, is selling all the 7 million shares in the offering. To gain access to Aduro's cancer immunotherapy technology, Novartis last month entered into a tie-up worth about $750 million with the company. Novartis Institutes for BioMedical Research Inc, an affiliate of Novartis,...

  • April 14- Aduro Biotech Inc's initial public offering has been priced at $17 per share, an underwriter said, valuing the cancer immunotherapy drug developer at about $1 billion. Aduro, which counts Johnson& Johnson and Novartis AG among its investors, is selling all the 7 million shares in the offering. The company had previously planned to sell 5 million shares...

  • *Novartis commits $225 mln upfront to private biotech firm. *Novartis also picks top scientist to lead immuno-oncology. March 30- Swiss drugmaker Novartis is digging deeper into cancer immunotherapy, one of the hottest areas of drug research, through a tie-up with Aduro Biotech worth up to $750 million.

  • Payout time in Europe as dividends soar Monday, 30 Mar 2015 | 6:42 AM ET

    Shareholder payouts by large companies in Europe soared over the last financial year, according to new research from Markit.

  • JERUSALEM, March 25- Israeli biopharmaceutical company BioLineRX Ltd said on Wednesday an early stage trial for a drug that uses stem cells to treat leukaemia and other blood cancers met all safety and efficacy goals. Current stem cell treatments require four or five days of injections of material from a donor to get into the bloodstream, but BioLineRX said its...